1.98% +0.0036

NLS Pharmaceutics Ltd (NLSP)

NLS Pharmaceutics Ltd Borsa (NLSP) Ultime notizie

NLS Pharmaceutics Ltd (NLSP)

NLS Pharmaceutics Ltd Borsa (NLSP) Ultime notizie

NLS Pharmaceutics Ltd (NLSP)'s highs and lows: A closer look at its stock price fluctuations – US Post News - US Post News

NLS Pharmaceutics Ltd (NLSP) Stock: A Year of Market Fluctuations - The InvestChronicle

NLS Pharmaceutics Ltd (NLSP) Stock: A Year of Highs and Lows - The InvestChronicle

Closing Bell Recap: NLS Pharmaceutics Ltd (NLSP) Ends at 0.14, Reflecting a -15.16 Downturn – DWinneX - The Dwinnex

NLS Pharmaceutics Announces CMO Resignation - TipRanks.com - TipRanks

NLS Pharmaceutics Ltd (NLSP) deserves deeper analysis – US Post News - US Post News

Deeper Dive: Understanding NLS Pharmaceutics Ltd (NLSP) Through its Various Ratios – DWinneX - The Dwinnex

NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Short Interest Up 182.0% in May - Defense World

NLS reports narcolepsy treatment progress at ASCP By Investing.com - Investing.com

Mazindol Shows Neuroprotective Benefits in Narcolepsy Treatment - Sleep Review

NLS Pharmaceutics Ltd Inc. (NLSP) Price Performance: A Technical Analysis Perspective - The InvestChronicle

NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic ... - Yahoo Finance

NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic ... - Yahoo Finance

NLS Pharmaceutics faces potential Nasdaq delisting By Investing.com - Investing.com

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - Yahoo Finance

NLS Pharmaceutics Ltd (NLSP) Recovers 53.41% From Low: Sitting In The Catbird Seat? – Stocks Register - Stocks Register

NLS Pharmaceutics faces potential Nasdaq delisting By Investing.com - Investing.com

NLS Pharmaceutics Ltd (NLSP)'s Ratio Roundup: Key Metrics for Trailing Twelve Months – DWinneX - The Dwinnex

Contrasting Xilio Therapeutics (NASDAQ:XLO) & NLS Pharmaceutics (NASDAQ:NLSP) - Defense World

NLS Pharmaceutics Ltd (NLSP) stock: A year of ups and downs – US Post News - US Post News

NLSP’s Stochastic Averages Dip: Analyzing NLS Pharmaceutics Ltd’s Stock Performance - The InvestChronicle

NLS Pharmaceutics (NASDAQ:NLSP) Stock Price Up 9.8% - Defense World

NLS Pharmaceutics (NASDAQ:NLSP) Stock Price Up 9.8% - Defense World

NLS Pharmaceutics Extends Loan Maturity Date - TipRanks.com - TipRanks

NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the ... - The Globe and Mail

NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice - The Globe and Mail

NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions - The Globe and Mail

Chronic Fatigue Syndrome Market to Witness Growth by 2032 | AIM Immunotech, Cortene, NLS Pharmaceutics - openPR

NLS Pharmaceutics Ltd (NLSP) deserves closer scrutiny – US Post News - US Post News

NLS Pharmaceutics Challenges Nasdaq Delisting - TipRanks.com - TipRanks

NLS Pharmaceutics faces Nasdaq delisting over share price - Investing.com South Africa

Board Member Resigns from NLS Pharmaceutics Ltd. - TipRanks.com - TipRanks

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering - Yahoo Finance

NLS Pharmaceutics Ltd. Announces New Warrant Issue - TipRanks.com - TipRanks

NLS Secures Exclusive License for Dual Orexin Agonist Platform - Sleep Review

NLS Pharmaceutics licenses Aexon's dual orexin receptor agonists - BioWorld Online

NLS Pharmaceutics Ltd. Addresses Financial Claims - TipRanks.com - TipRanks

NLS Pharmaceutics Expands Neurological Therapy Options - TipRanks.com - TipRanks

NLS Pharmaceutics Extends Loan Maturity Date - TipRanks.com - TipRanks

NLS secures rights from Aexon to novel neuropharmacological agents By Investing.com - Investing.com

NLS Pharmaceutics regains Nasdaq listing compliance By Investing.com - Investing.com

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq - Yahoo Finance

Notice of Deficiency with Nasdaq Continued Listing Requirements - Yahoo Finance

NLS Pharmaceutics, Whose Narcolepsy Drug Candidate Is In Clinical Trials, Recaps 2023 - Sleep Review

NLS Pharmaceutics Acquires Rights to Orexin Agonist Platform - Sleep Review

Spotify Layoffs 2023: What to Know About the Latest SPOT Job Cuts - InvestorPlace

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual ... - Yahoo Finance

NLS Out-Licenses Mazindol As It Explores Strategic Alternatives - Sleep Review

Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day ... - Markets Insider

NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification - Yahoo Finance

Simile a NLSP